Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 in advanced solid tumors and lymphoma
NCT03733951Phase 1Completed
- Sponsor
- Alphamab Oncology
- Start
- Dec 2018
- Primary completion
- Jan 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erfonrilimab in solid tumor (advanced stage) and lymphoma, sponsored by Alphamab Oncology. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Objective Response Rate at 2 years and 1 more. Started Dec 2018; status: completed.
02
Drugs
erfonrilimab
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT03733951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733951.